Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis

[1] van den Hoogen F(2013)2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 65 2737-2747

[2] Khanna D(2020)Pathogenesis of systemic sclerosis associated interstitial lung disease J Scleroderma Relat Disord 5 6-16

[3] Fransen J(2019)Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort Am J Respir Crit Care Med 200 1258-1266

[4] Johnson SR(2012)Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis Arthritis Care Res (Hoboken) 64 519-524

[5] Baron M(2005)Autoantibodies in systemic sclerosis Semin Arthritis Rheum 35 35-42

[6] Tyndall A(2014)Prediction of pulmonary complications and long-term survival in systemic sclerosis Arthritis Rheumatol 66 1625-1635

[7] Nihtyanova SI(2016)Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study PLoS One 11 e0163894-3261

[8] Denton CP(2018)Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China Arthritis Res Ther 20 235-1576

[9] Hoffmann-Vold AM(2015)Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease Arthritis Rheumatol 67 3256-1254

[10] Fretheim H(2018)Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis J Rheumatol 45 1572-160

[1] van den Hoogen F(2013)2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 65 2737-2747

[2] Khanna D(2020)Pathogenesis of systemic sclerosis associated interstitial lung disease J Scleroderma Relat Disord 5 6-16

[3] Fransen J(2019)Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort Am J Respir Crit Care Med 200 1258-1266

[4] Johnson SR(2012)Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis Arthritis Care Res (Hoboken) 64 519-524

[5] Baron M(2005)Autoantibodies in systemic sclerosis Semin Arthritis Rheum 35 35-42

[6] Tyndall A(2014)Prediction of pulmonary complications and long-term survival in systemic sclerosis Arthritis Rheumatol 66 1625-1635

[7] Nihtyanova SI(2016)Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study PLoS One 11 e0163894-3261

[8] Denton CP(2018)Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China Arthritis Res Ther 20 235-1576

[9] Hoffmann-Vold AM(2015)Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease Arthritis Rheumatol 67 3256-1254

[10] Fretheim H(2018)Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis J Rheumatol 45 1572-160